RAPP News & Events

Rapport Therapeutics announced plans to initiate its Phase 3 program for RAP-219 in FOS in the second quarter of 2026 and expand its epilepsy portfolio with a new program in PGTCS. Additionally, the Company announced progress across its pipeline, including its Phase 2 bipolar mania trial, long-acting injectable development, FDA's removal of the clinical hold on its Phase 2 diabetic peripheral neuropathic pain trial, and advancement of additional pipeline programs.

Rapport Therapeutics announced new data and post hoc analysis on clinical and patient reported benefits of RAP-219 in drug-resistant focal onset seizures, FOS, alongside topline efficacy and safety data from its recently reported Phase 2a FOS trial. The results were presented at the 2025 American Epilepsy Society, AES, Annual Meeting and include RAP-219's early treatment effects and consistent median efficacy data across the full treatment period, its performance across varying levels of baseline disease severity, and its impact on seizure severity. Rapport announced topline results from the Phase 2a study in September 2025. The trial enrolled 30 participants and met the primary endpoint, demonstrating a statistically significant reduction in long episodes compared with baseline over the 8-week treatment period. Study participants achieved a 77.8% reduction in clinical seizures compared with baseline, with 24% achieving seizure freedom during the 8-week treatment period. RAP-219 was generally well-tolerated in the trial, with the majority of treatment-emergent adverse events being mild and a low discontinuation rate.